ClinicalTrials.gg
RecruitingNCT06526533RECOMMENDUpdated May 13, 2026

RECOMMEND Platform Trial

A Phase 3 interventional study of Liberal RBC Transfusion and Restrictive RBC Transfusion in Extracorporeal Membrane Oxygenation Complication, ARDS (Acute Respiratory Distress Syndrome) and Intensive Care Medicine, sponsored by Australian and New Zealand Intensive Care Research Centre. Recruiting at 3 sites in Australia. Per ClinicalTrials.gov, last updated 2026-05-13.

Sponsored by Australian and New Zealand Intensive Care Research Centre · Phase 3, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
600
Allocation
Randomized
Sex
All
01

Study summary

The goal of this platform trial is to determine the efficacy, safety and cost-effectiveness of various interventions in patients with acute cardiorespiratory failure requiring extracorporeal membrane oxygenation (ECMO)

The main question the platform trial aims to address is to determine the effect of a range of interventions on survival, organ support and resource utilisation to day 28 for hospitalised patients receiving ECMO.

Researchers will compare various interventions within multiple platform trial domains to see if the interventions have effects on survival, organ support and resource utilisation for the patient cohort.

Participants will be enrolled in accordance with the platform trial's domain structure to answer the research questions.

Read the detailed description

The RECOMMEND Platform trial is an investigator initiated, multicentre, open labelled, randomised controlled Platform Trial that will utilise Bayesian adaptive logic to investigate the efficacy and safety of multiple study interventions simultaneously or sequentially in cohorts of adult patients who are receiving ECMO from ICUs participating in the national ECMO registry (EXCEL) in Australian hospitals (EXCEL Registry NCT03793257).

In this platform trial, various interventions will be investigated for their potential to improve outcomes for patients undergoing ECMO.

Extracorporeal Membrane Oxygenation (ECMO) is an invasive and resource intensive treatment used to support critically ill patients suffering from severe cardiac arrest, cardiac failure or respiratory failure. ECMO provides mechanical circulatory support, temporarily replacing the function of the heart and/or lungs, allowing time for these organs to recover.

Globally, the use of ECMO has increased rapidly over the past decade. It is both invasive and expensive, with the average cost for a single admission in Australia exceeding more than $180,000 and a total annual cost of > $75 million. Despite its high cost, ECMO is associated with a high mortality rate, and many survivors have compromised functional recovery for months or years after discharge from hospital, further adding to the long-terms costs of care.

The main complications reported in the national ECMO registry from 2019-2022 include bleeding (51.4%), renal failure and fluid overload (78.4%), and death and ongoing disability (66%). These were confirmed as research priorities by consumers and end-users. While the use of ECMO increases swiftly, the evidence base to support the growing patient numbers receiving this care has not grown at the same rate, resulting in important evidence gaps.

The RECOMMEND Platform Trial will address these evidence gaps in ECMO services in Australia. A platform trial is a type of study design that evaluates multiple treatment interventions for a single condition or device simultaneously within a single, overarching framework. This framework operates similarly to a standard operating procedure for study logistics, ethics management, funding, staffing, and statistical and data collection methods. Having an approved process (platform) for the 'Platform Trial' to operate saves time and money and increases speed of clinical trial onboarding to outcome resolution for researchers, hospital staff, ethics committees, and stakeholders. With this platform in place, future studies of similar ECMO outcomes can be onboarded more efficiently, as described above, and it creates a more powerful pool of data for impactful patient-centred research.

Over the lifetime of RECOMMEND, it is anticipated that new interventions will be added as new domains. The creation of new domains will be considered according to priorities set by relevant working groups, based on existing or new clinical need and there being sufficient statistical power available within RECOMMEND.

02

Conditions studied

  • Extracorporeal Membrane Oxygenation Complication
  • ARDS (Acute Respiratory Distress Syndrome)
  • Intensive Care Medicine
  • Cardiac Arrest (CA)
  • Critical Illness

Keywords

  • ECMO
  • ICU
  • Platform Trial
  • Australia
  • Cardiac
  • Respiratory
  • VA
  • VV
  • eCPR
  • Adaptive
03

In context

Acute Lung Injury

382 studies on the registry are indexed under Acute Lung Injury; 73 are open to participants now.

This study's planned enrollment of 600 is above the median of 60 across 227 interventional studies indexed under Acute Lung Injury.

Browse Acute Lung Injury studies →

Lead sponsor

Australian and New Zealand Intensive Care Research Centre is the lead sponsor of 49 studies on the registry; 16 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

PLATFORM INCLUSION CRITERIA:

  • Patients receiving ECMO
  • Patients enrolled in the EXCEL Registry - NCT03793257

PLATFORM EXCLUSION CRITERIA:

  • Treating clinician regards death as imminent and inevitable
  • Treating clinician determines it is not in the patient's best interests

RBC TRANSFUSION DOMAIN INCLUSION CRITERIA:

  • Aged 18 years or older

RBC TRANSFUSION DOMAIN EXCLUSION CRITERIA:

  • to RBC transfusion (including known patient preference)
  • Limitations of care put in place either through patient wishes or the treating medical teams.
  • Participant has already received ECMO >12 hours. The start of ECMO is defined as the time of initiation of extracorporeal blood flow unless ECMO was initiated during a surgical intervention in which case the start of ECMO is defined as the arrival time into the initial ICU (post-surgery)
  • The treating physician anticipates that ECMO treatment will cease before the end of tomorrow
  • The treating physician deems the study is not in the patient's best interest
  • The treating physician has concern regarding patient ability to tolerate restrictive or liberal transfusion trigger thresholds
  • Actively listed for a solid organ transplant and has not yet received one
  • Suspected or confirmed to be pregnant
  • Previous ECMO treatment during the same hospital admission
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
600 participants (estimated)

Study arms

  • Other
    Participant Group/Arm

    RBC Transfusion Domain: Patients on ECMO in ICU enrolled in the RBC Transfusion Domain of RECOMMEND. Patients receive one of two RBC transfusion strategies (restrictive or liberal)

    Other: Liberal RBC Transfusion · Other: Restrictive RBC Transfusion

Interventions

  • OtherLiberal RBC Transfusion

    Liberal transfusion trigger group (patient receives RBC transfusion if Hb \<90g/L).

  • OtherRestrictive RBC Transfusion

    Restrictive transfusion trigger group (patient receives RBC transfusion if Hb \<70g/L).

06

What researchers measure

Primary outcomes

  1. Daily Organ Support for patients on ECMO (DOSE-score).

    The primary outcome is the Daily Organ Support for patients on ECMO (DOSE-score), a 6-level daily ordinal outcome measured as the worst status of a patient on each day from day 1 through to day 28 inclusive, which reflects survival, organ support and resource utilisation: 1. dead; 2. on ECMO; 3. invasively mechanically ventilated without ECMO; 4. in ICU but not invasively mechanically ventilated nor on ECMO; 5. in hospital; and 6. discharged from the hospital alive.

    Time frame: 28-days.

Secondary outcomes

  1. Development of major haemorrhage at 28 days

    Development of major haemorrhage

    Time frame: 28-days.

  2. Development of intracranial haemorrhage at 28 days

    Development of intracranial haemorrhage

    Time frame: 28 days

  3. Mortality at 28 days

    Living status.

    Time frame: 28 days

  4. ECMO-free days at 28 days

    Number of days not receiving ECMO

    Time frame: 28 days

  5. Ventilator-free days at 28 days

    Number of days not receiving ventilation

    Time frame: 28 days

Other outcomes

  1. Mortality at 180 days

    Platform Trial Tertiary Outcome

    Time frame: 180 days

  2. Disability at 180 days

    Platform Trial Tertiary Outcome - measured by WHODAS 2.0 at 180-days

    Time frame: 180 days

  3. Functional Status at 180 days

    Platform Trial Tertiary Outcome - measured using Lawton-Brody IADL and Barthel ADL

    Time frame: 180 days

  4. Quality of Life at 180 days

    Platform Trial Tertiary Outcome - measured by Eq-5D-5L and EQ-VAS

    Time frame: 180 days

  5. ICU Length of Stay

    Platform Trial Tertiary Outcome

    Time frame: 180 days

  6. Hospital Length of Stay

    Platform Trial Tertiary Outcome - separated for survivors and non-survivors

    Time frame: 180 days

  7. Number and Nature of SAEs

    RBC Transfusion Domain Specific Outcome

    Time frame: 28 days

  8. Mortality in ICU

    RBC Transfusion Domain Specific Outcome

    Time frame: 180 days

  9. Total Blood Products

    RBC Transfusion Domain Specific Outcome - administered until cessation of ECMO or 28 days, whichever occurs first

    Time frame: 28 days

  10. Total RBC Units

    RBC Transfusion Domain Specific Outcome - administered until cessation of ECMO or 28 days, whichever occurs first

    Time frame: 28 days

07

Study locations

1 of 3 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — No IPD is created as individual data are not shared. However, aggregated data presented in manuscripts and publications or similar works, will be accessible upon patient request or own investigation.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2026 (actual). Primary completion is estimated for Jun 2028, 27 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 25, 2024
First posted
Jul 30, 2024
StartActual
Mar 23, 2026
Primary completionEst.
Jun 2028
CompletionEst.
Jun 2029
Last update
May 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06526533
Lead sponsor
Australian and New Zealand Intensive Care Research Centre
Collaborators
Monash University, Berry Consultants, Research Path
Responsible party
Sponsor
First posted
Jul 30, 2024
Start date
Mar 23, 2026
Primary completion
Jun 2028 (estimated)
Completion
Jun 2029 (estimated)
Last update
May 13, 2026

Study contacts

Curtis Hopkins, B.BioMed, MPH, MHA
Contact
curtis.hopkins@monash.edu
+61 3 9903 0343
Carol Hodgson, PhD FACP FAHMS
Contact
carol.hodgson@monash.edu
+61 3 9903 0598
Carol Hodgson, PhD FACP FAHMS
study chair · Monash University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion